Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Bought by Dorsey & Whitney Trust CO LLC

Dorsey & Whitney Trust CO LLC grew its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBHFree Report) by 6.7% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,812 shares of the medical equipment provider’s stock after acquiring an additional 304 shares during the period. Dorsey & Whitney Trust CO LLC’s holdings in Zimmer Biomet were worth $540,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the business. Banque Cantonale Vaudoise increased its holdings in shares of Zimmer Biomet by 37.8% during the 3rd quarter. Banque Cantonale Vaudoise now owns 17,094 shares of the medical equipment provider’s stock valued at $1,918,000 after acquiring an additional 4,690 shares during the last quarter. First Command Advisory Services Inc. bought a new position in shares of Zimmer Biomet in the third quarter valued at approximately $172,000. Greatmark Investment Partners Inc. boosted its holdings in shares of Zimmer Biomet by 2.7% during the 3rd quarter. Greatmark Investment Partners Inc. now owns 13,810 shares of the medical equipment provider’s stock worth $1,550,000 after buying an additional 365 shares during the period. Amalgamated Bank grew its stake in Zimmer Biomet by 3.0% in the 3rd quarter. Amalgamated Bank now owns 56,166 shares of the medical equipment provider’s stock valued at $6,303,000 after buying an additional 1,631 shares during the last quarter. Finally, Western Wealth Management LLC bought a new position in Zimmer Biomet in the 3rd quarter worth $481,000. Institutional investors and hedge funds own 87.48% of the company’s stock.

Zimmer Biomet Stock Down 0.8 %

Shares of NYSE:ZBH opened at $125.36 on Tuesday. The company has a quick ratio of 0.99, a current ratio of 2.11 and a debt-to-equity ratio of 0.41. The firm has a market cap of $26.20 billion, a P/E ratio of 55.47, a P/E/G ratio of 2.32 and a beta of 1.03. The company’s 50-day moving average price is $120.59 and its two-hundred day moving average price is $117.80. Zimmer Biomet Holdings, Inc. has a 12 month low of $102.00 and a 12 month high of $149.25.

Zimmer Biomet (NYSE:ZBHGet Free Report) last released its earnings results on Tuesday, November 7th. The medical equipment provider reported $1.65 EPS for the quarter, beating the consensus estimate of $1.59 by $0.06. Zimmer Biomet had a return on equity of 12.41% and a net margin of 6.52%. The company had revenue of $1.75 billion during the quarter, compared to analysts’ expectations of $1.75 billion. During the same period last year, the firm earned $1.58 EPS. The business’s revenue for the quarter was up 5.0% on a year-over-year basis. As a group, research analysts forecast that Zimmer Biomet Holdings, Inc. will post 7.51 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, January 31st. Shareholders of record on Wednesday, December 27th were given a dividend of $0.24 per share. The ex-dividend date was Tuesday, December 26th. This represents a $0.96 dividend on an annualized basis and a yield of 0.77%. Zimmer Biomet’s payout ratio is presently 42.48%.

Wall Street Analyst Weigh In

ZBH has been the topic of a number of recent analyst reports. Royal Bank of Canada lifted their price objective on Zimmer Biomet from $134.00 to $140.00 and gave the stock an “outperform” rating in a research note on Friday, January 12th. JMP Securities cut their price target on Zimmer Biomet from $160.00 to $140.00 and set a “market outperform” rating for the company in a report on Monday, November 13th. Raymond James raised their price objective on shares of Zimmer Biomet from $133.00 to $137.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 3rd. Truist Financial increased their price target on shares of Zimmer Biomet from $115.00 to $133.00 and gave the company a “hold” rating in a report on Friday, December 22nd. Finally, Roth Mkm assumed coverage on shares of Zimmer Biomet in a report on Friday, October 20th. They set a “neutral” rating and a $120.00 price objective on the stock. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $137.60.

View Our Latest Stock Analysis on Zimmer Biomet

Zimmer Biomet Profile

(Free Report)

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

Further Reading

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.